CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 81 enrolled
Drug / intervention
Abiraterone acetate 1000 mg po daily +2 moredrug
Likely dose
Abiraterone acetate 1000 mg po dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02218606
NCT02218606Phase 2Completed
CompareCT.gov

An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Aug 18, 2014·Updated Dec 10, 2024

In Brief

A Phase 2 clinical trial evaluating Abiraterone acetate 1000 mg po daily, Cabazitaxel 25 mg/m2 IV, and 1 other intervention for Prostate Cancer. Completed, enrolled 81 participants across 4 sites.

Detailed Summary

The purpose of this study is to see what effects (good and bad) treatment with abiraterone acetate (an oral hormonal agent) and prednisone (a steroid) with and without cabazitaxel (a chemotherapy) have on the cancer and to find out more about whether specific laboratory tests on tumor are useful in predicting how the patient will respond to treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsSanofi, Thomas Jefferson University, Weill Medical College of Cornell University

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 18, 2014
Enrollment StartAug 1, 2014
Primary CompletionOct 13, 2023
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 11.9 years ago

Interventions

Abiraterone acetate 1000 mg po dailydrug

Cabazitaxel 25 mg/m2 IVdrug

prednisone 5 mg po BIDdrug